Related Experiment Video

Updated: Aug 26, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy

M Chand, M Thakuri, Y-K Keung

    Leukemia
    |February 13, 2004
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Aug 26, 2026

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

    Articles linked to this work by shared authors, journal, and citation graph.

    Preliminary validity evidence for a platform-specific assessment tool for robotic setup and docking.

    Journal of robotic surgery·2026

    Colorectal anastomotic safety assessment using ICG fluorescence and flexible endoscopy (COLOSSEUM): a global survey of 1367 surgeons.

    Surgical endoscopy·2026

    Benchmarking variability in semantic segmentation in minimally invasive abdominal surgery.

    International journal of computer assisted radiology and surgery·2026

    Development of a platform-specific objective assessment tool for the accreditation of robotic setup and docking.

    Surgical endoscopy·2025

    Acclimatising with 3D virtual reality video improves simulator performance: initial findings of a randomised controlled feasibility trial.

    Surgical endoscopy·2025

    Standardising robotic system setup: an international expert consensus.

    Surgical endoscopy·2025

    Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.

    Leukemia·2026

    Cheminformatic identification of small molecules targeting acute myeloid leukemia.

    Leukemia·2026

    Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.

    Leukemia·2026

    Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

    Leukemia·2026

    PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.

    Leukemia·2026

    TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

    Leukemia·2026

    [Development of universal off-the-shelf T cell therapies derived from ES/iPS cells for leukemia and COVID-19].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    [Intrathecal immunoglobulin administration for refractory viral central nervous system infection after allogeneic hematopoietic stem cell transplantation].

    [Rinsho ketsueki] The Japanese journal of clinical hematology·2026

    Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.

    Journal of the American College of Cardiology·2026

    Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy: A Meta-Analysis of Outcomes Trials.

    JAMA·2026

    Advanced therapy medicinal products in Saudi Arabia: Regulation and development.

    Regenerative therapy·2026

    289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands.

    Neuromuscular disorders : NMD·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us